Jahnavi Sarma
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Jahnavi Sarma | Updated : January 9, 2021 9:52 AM IST
Fake Covid-19 vaccines reportedly offered for sale on the dark net with price tags of up to $1,000 for a dose.
Days after getting the Drugs Controller General of India's (DCGI) nod for India's first indigenously made COVID-19 vaccine, Bharat Biotech has again knocked on the doors of the drug controller seeking permission to conduct clinical trials of their intranasal vaccine for the viral disease. Hyderabad-based Bharat Biotech has applied to the DGCI for permission to start Phase 1 and 2 trials of their nasal coronavirus vaccine, top sources privy to the development told IANS.
As the name suggests, a nasal vaccine is administered via the nose. This is a non-invasive and painless method of vaccine delivery as it does not require a needle. This kind of vaccine induces immunity through the inner surface of the nose, which is the place that is exposed to airborne microbes. Here is what we know about the nasal vaccine.
Clinical trials of the 'BBV154' - a novel adenovirus vectored, intranasal vaccine for coronavirus -- will be conducted at various locations. The vaccine will be a single-dose one. According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of COVID-19.
The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.
The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunised with its single dose conferred superior protection against SARS-CoV-2 challenge, "more so than one or two intramuscular immunisations of the same vaccine and dose".
Intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission," Bharat Biotech said in a statement.
On January 3, two intramuscular vaccines - Bharat Biotech's Covaxin and Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India - were approved for restricted emergency use. Both are two-dose vaccines. While the full efficacy of Covaxin is yet to be determined, it was given the go-ahead by the DCGI citing 'public interest'. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).
(With inputs from IANS)
